Aranesp and Lymphoma - a phase IV clinical study of FDA data

Summary:

Lymphoma is reported as a side effect among people who take Aranesp (darbepoetin alfa), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Zometa, and have Bone disorder.

The phase IV clinical study analyzes which people have Lymphoma when taking Aranesp. It is created by eHealthMe based on reports of 54,218 people who have side effects when taking Aranesp from the FDA, and is updated regularly.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.

What is Lymphoma?

Lymphoma (cancer that begins in immune system cells) is found to be associated with 958 drugs and 1,013 conditions by eHealthMe. Check the latest studies of Lymphoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

54,218 people reported to have side effects when taking Aranesp.
Among them, 60 people (0.11%) have Lymphoma.

Among these 60 people:

How long have people been on Aranesp when they have Lymphoma? *

What is the gender of people who have Lymphoma when taking Aranesp? *

female: 39.66 %
male: 60.34 %

What is the age of people who have Lymphoma when taking Aranesp? *

What are other drugs people take besides Aranesp? *

What are other side effects people have besides Lymphoma? *

Pneumonia: 23 people, 38.33%
Anaemia (lack of blood): 23 people, 38.33%
Pain: 21 people, 35.00%
Infection: 21 people, 35.00%
Osteonecrosis Of Jaw (death of bone of jaw): 20 people, 33.33%
Diarrhea: 19 people, 31.67%
Deformity (disfigurement): 18 people, 30.00%
Thrombocytopenia (decrease of platelets in blood): 18 people, 30.00%
Metastases To Bone (cancer spreads to bone): 17 people, 28.33%
Urinary Tract Infection: 16 people, 26.67%

What are the existing conditions these people have? *

Bone Disorder: 11 people, 18.33%
Anaemia Of Malignant Disease: 6 people, 10.00%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 4 people, 6.67%
Chronic Renal Failure (kidney failure): 4 people, 6.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 3.33%
Multiple Myeloma (cancer of the plasma cells): 2 people, 3.33%
Metastases To Bone (cancer spreads to bone): 2 people, 3.33%
Hiv Infection: 2 people, 3.33%
Suicide Attempt: 1 person, 1.67%
High Blood Pressure: 1 person, 1.67%

* Approximation only. Some reports may have incomplete information.

Do you take Aranesp and have Lymphoma?

- Check whether Lymphoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aranesp:

Aranesp (54,331 reports)

Lymphoma treatments and more:

Lymphoma (33,395 reports)

Browse all side effects of Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lymphoma:

Lymphoma (958 drugs)

Browse all the conditions that are associated with Lymphoma:

Lymphoma (1,013 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .

How the study uses the data?

The study uses data from the FDA. It is based on darbepoetin alfa (the active ingredients of Aranesp) and Aranesp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.